Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial (colistin)

Beni-Suef University

Status and phase: Completed; Phase 3

Conditions: Secondary Bacterial Infection in COVID-19 Patients

Treatments: Drug: Colistin

Study type: Interventional

Funder types: Other

Identifiers

NCT05689229

BSU-22006

Details and patient eligibility

About

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

Enrollment: 128 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Covid-19 patients with secondary gram-negative bacterial infections

Exclusion criteria

• Patients with resistant bacterial strains to polymyxins
• patients less than 18 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

128 participants in 3 patient groups

Colistin IV

Active Comparator group

Treatment:

Drug: Colistin

Colistin Aerosolized

Active Comparator group

Treatment:

Drug: Colistin

Control

No Intervention group